Protagenic Therapeutics, Inc. (PTIX)
- Previous Close
11.10 - Open
8.69 - Bid 8.61 x 100
- Ask --
- Day's Range
8.10 - 9.86 - 52 Week Range
2.35 - 26.18 - Volume
1,489,923 - Avg. Volume
2,053,083 - Market Cap (intraday)
5.227M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-13.13 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
www.protagenic.comRecent News: PTIX
View More
Performance Overview: PTIX
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTIX
View MoreValuation Measures
Market Cap
6.54M
Enterprise Value
1.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-189.60%
Return on Equity (ttm)
-512.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.24M
Diluted EPS (ttm)
-13.13
Balance Sheet and Cash Flow
Total Cash (mrq)
872.96k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.79M